Sign up
Pharma Capital

ANGLE to offer a full liquid biopsy 'sample to answer' solution following Axela acquisition

Andrew Newland, chief executive of ANGLE PLC (LON:AGL) (OTCQX:ANPCY) managed to find a quiet corner at Gatwick Airport, just minutes before flying out to Europe's leading CTC conference in Rhodes, to discuss their decision to acquire some assets from a Canadian company with intellectual property that complements ANGLE’s Parsortix liquid biopsy platform.

ANGLE is paying C$6.16mln, or roughly £3.7mln, for the assets.

Eight of the Axela team will be moving on to ANGLE’s payroll.

The Axela system will complement Parsortix by providing an analysis element to ANGLE’s offering, enabling the UK company to capture a greater proportion of the liquid biopsy value chain.


View full AGL profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.